JP7311113B2 - Ｉｌ－６及びｃｄ１２６を標的とするｄｎａモノクローナル抗体 - Google Patents

Ｉｌ－６及びｃｄ１２６を標的とするｄｎａモノクローナル抗体 Download PDF

Info

Publication number
JP7311113B2
JP7311113B2 JP2019510567A JP2019510567A JP7311113B2 JP 7311113 B2 JP7311113 B2 JP 7311113B2 JP 2019510567 A JP2019510567 A JP 2019510567A JP 2019510567 A JP2019510567 A JP 2019510567A JP 7311113 B2 JP7311113 B2 JP 7311113B2
Authority
JP
Japan
Prior art keywords
seq
composition
nucleic acid
nucleotide sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019510567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518074A (ja
Inventor
ビー．ウェイナー デイビッド
エリオット サラ
Original Assignee
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア, ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー filed Critical ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Publication of JP2019518074A publication Critical patent/JP2019518074A/ja
Priority to JP2023051617A priority Critical patent/JP2023086734A/ja
Application granted granted Critical
Publication of JP7311113B2 publication Critical patent/JP7311113B2/ja
Priority to JP2025077437A priority patent/JP2025147175A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019510567A 2016-05-05 2017-05-05 Ｉｌ－６及びｃｄ１２６を標的とするｄｎａモノクローナル抗体 Active JP7311113B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023051617A JP2023086734A (ja) 2016-05-05 2023-03-28 Ｉｌ－６及びｃｄ１２６を標的とするｄｎａモノクローナル抗体
JP2025077437A JP2025147175A (ja) 2016-05-05 2025-05-07 Ｉｌ－６及びｃｄ１２６を標的とするｄｎａモノクローナル抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332377P 2016-05-05 2016-05-05
US62/332,377 2016-05-05
PCT/US2017/031193 WO2017192933A1 (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023051617A Division JP2023086734A (ja) 2016-05-05 2023-03-28 Ｉｌ－６及びｃｄ１２６を標的とするｄｎａモノクローナル抗体

Publications (2)

Publication Number Publication Date
JP2019518074A JP2019518074A (ja) 2019-06-27
JP7311113B2 true JP7311113B2 (ja) 2023-07-19

Family

ID=60203626

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019510567A Active JP7311113B2 (ja) 2016-05-05 2017-05-05 Ｉｌ－６及びｃｄ１２６を標的とするｄｎａモノクローナル抗体
JP2023051617A Pending JP2023086734A (ja) 2016-05-05 2023-03-28 Ｉｌ－６及びｃｄ１２６を標的とするｄｎａモノクローナル抗体
JP2025077437A Pending JP2025147175A (ja) 2016-05-05 2025-05-07 Ｉｌ－６及びｃｄ１２６を標的とするｄｎａモノクローナル抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023051617A Pending JP2023086734A (ja) 2016-05-05 2023-03-28 Ｉｌ－６及びｃｄ１２６を標的とするｄｎａモノクローナル抗体
JP2025077437A Pending JP2025147175A (ja) 2016-05-05 2025-05-07 Ｉｌ－６及びｃｄ１２６を標的とするｄｎａモノクローナル抗体

Country Status (12)

Country Link
US (1) US20190192692A1 (enExample)
EP (1) EP3452106A4 (enExample)
JP (3) JP7311113B2 (enExample)
KR (3) KR20250011241A (enExample)
CN (1) CN109789224A (enExample)
AU (2) AU2017261292B2 (enExample)
BR (1) BR112018072697A2 (enExample)
CA (1) CA3023089A1 (enExample)
EA (1) EA201892524A1 (enExample)
MX (2) MX2018013523A (enExample)
SG (2) SG11201809786TA (enExample)
WO (1) WO2017192933A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210117359A (ko) * 2016-11-07 2021-09-28 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 라임병에 사용하기 위한 dna 항체 작제물
KR102635888B1 (ko) 2019-03-19 2024-02-15 엘지전자 주식회사 공기청정기
EP4277929A1 (en) * 2021-01-14 2023-11-22 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518023A (ja) 2005-12-09 2009-05-07 ユセベ ファルマ ソシエテ アノニム ヒトｉｌ−６に対して特異性を有する抗体分子
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
JP2011520898A (ja) 2008-05-13 2011-07-21 ノビミューン エスアー 抗ｉｌ−６／ｉｌ−６ｒ抗体およびそれらの使用方法
US20120128626A1 (en) 2010-11-23 2012-05-24 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
JP2016501535A (ja) 2012-12-13 2016-01-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｄｎａ抗体構築物およびその使用方法
JP2016530318A (ja) 2013-09-11 2016-09-29 アーシア セラピューティクス， インコーポレイテッド 水溶性有機色素を含有する液状タンパク質製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2318829C2 (ru) * 2001-11-14 2008-03-10 Сентокор, Инк. Антитела против il-6, композиции, способы и применение
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
CA2657763C (en) * 2006-08-03 2016-05-31 Vaccinex Inc. Anti-il-6 monoclonal antibodies and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518023A (ja) 2005-12-09 2009-05-07 ユセベ ファルマ ソシエテ アノニム ヒトｉｌ−６に対して特異性を有する抗体分子
JP2011520898A (ja) 2008-05-13 2011-07-21 ノビミューン エスアー 抗ｉｌ−６／ｉｌ−６ｒ抗体およびそれらの使用方法
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
US20120128626A1 (en) 2010-11-23 2012-05-24 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
JP2016501535A (ja) 2012-12-13 2016-01-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｄｎａ抗体構築物およびその使用方法
JP2016530318A (ja) 2013-09-11 2016-09-29 アーシア セラピューティクス， インコーポレイテッド 水溶性有機色素を含有する液状タンパク質製剤

Also Published As

Publication number Publication date
EP3452106A1 (en) 2019-03-13
CA3023089A1 (en) 2017-11-09
KR20190031439A (ko) 2019-03-26
JP2025147175A (ja) 2025-10-06
JP2019518074A (ja) 2019-06-27
EP3452106A4 (en) 2020-01-08
MX2018013523A (es) 2019-06-10
SG10202011023YA (en) 2020-12-30
US20190192692A1 (en) 2019-06-27
CN109789224A (zh) 2019-05-21
AU2024203109A1 (en) 2024-05-30
AU2017261292B2 (en) 2024-06-06
AU2017261292A1 (en) 2018-12-20
JP2023086734A (ja) 2023-06-22
KR20250011241A (ko) 2025-01-21
BR112018072697A2 (pt) 2019-02-19
WO2017192933A1 (en) 2017-11-09
MX2025009846A (es) 2025-09-02
KR20230058733A (ko) 2023-05-03
EA201892524A1 (ru) 2019-04-30
SG11201809786TA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
JP2023086734A (ja) Ｉｌ－６及びｃｄ１２６を標的とするｄｎａモノクローナル抗体
CN110325546B (zh) 靶向流感病毒的dna单克隆抗体
US20240376179A1 (en) Dna antibody constructs for use against middle east respiratory syndrome coronavirus
JP2023126321A (ja) ライム病に対する使用のためのｄｎａ抗体構築物
US12162925B2 (en) DNA-encoded monoclonal antibodies targeting the Ebolavirus glycoprotein
US20210047390A1 (en) Nucleic acid antibody constructs for use against respiratory syncytial virus
US20230340082A1 (en) Dna antibody constructs for use against rotavirus
RU2813829C2 (ru) Конструкции днк-антител для применения против болезни лайма
HK40009046A (en) Dna monoclonal antibodies targeting il-6 and cd126
EA042308B1 (ru) Днк-моноклональные антитела, нацеленные на il-6
HK40013455A (en) Dna antibody constructs for use against lyme disease
WO2019152602A1 (en) Structurally modified flavivirus dmabs
US20210047388A1 (en) Nucleic acid antibody constructs for use against ebola virus
HK40016025A (en) Dna monoclonal antibodies targeting influenza virus
KR20190114963A (ko) 에볼라 바이러스에 대한 사용을 위한 dna 항체 작제물

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220729

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230328

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230328

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230411

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230509

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230530

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230628

R150 Certificate of patent or registration of utility model

Ref document number: 7311113

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150